Necrotising enterocolitis biomarkers: a systematic review
Frontiers in Pediatrics · 12.01.2026 · 13
DOI: 10.3389/fped.2025.1652566 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pediatrics, online erschienen am 12.01.2026. Verfasst von Muhammad Ashhad Faizan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, University of Dublin, Trinity College, Dublin, Ireland. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Necrotising enterocolitis (NEC) is a severe acute inflammatory condition of the gastrointestinal tract that predominantly affects preterm neonates. The variable and often nonspecific clinical signs, followed by rapid progression into fulminant disease, and the lack of standardised definitions and biomarkers, make this condition notoriously difficult to diagnose. This systematic review aims to outline the inflammatory pathways involved in the pathogenesis of NEC and to identify potential biomarkers associated with the initial stages of disease progression.
Methods
Following the PRISMA guidelines, we conducted an electronic search of the available literature using the PubMed, Embase, and Cochrane electronic databases with the following search terms (“necrotizing enterocolitis” OR “necrotising enterocolitis” OR “NEC”) AND (“biomarker*” OR “biological marker”). Studies reporting data on the diagnostic accuracy of biomarkers for NEC were included. Results were restricted to full-text articles in English, available up to November 2024. Risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool.
Results
A total of 211 studies were screened, yielding 79 studies for analysis. Most studies evaluated the ability of biomarkers to differentiate Bell's stage ≥II NEC from controls or Bell's stage II from stage III. For identifying Bell's stage ≥II, faecal calprotectin (97.14% sensitivity, 100% specificity) and serum calprotectin (100% sensitivity, 96.4% specificity), as well as a panel consisting of urine proteins including Cystatin C (CST3), Pigment Epithelium Derived Factor (PEDF), and Retinol Binding Protein 4 (RET4) (96% sensitivity, 90% specificity), and maternal human milk oligosaccharide disialyllacto-N-tetraose DSNLT (90% sensitivity and specificity) demonstrated high sensitivity and specificity when sampled prior to or around the initial diagnosis of NEC. Interleukin 33 (IL-33) exhibited high accuracy. Systematic Review Registration PROSPERO CRD42024307046.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Paediatrics, University of Dublin, Trinity College, Dublin, Ireland.
- Trinity College Dublin Trinity Translational Medicine Institute, Dublin, Ireland.
- Neurodisability Children's Health Ireland (CHI) at Temple Street, Dublin, Ireland.
- Paediatric Endocrinology, Children's Health Ireland (CHI) at Temple Street, Dublin, Ireland.
- Neonatology, CHI at Crumlin, Dublin, Ireland.
- The Coombe Hospital, Dublin, Ireland.
Zitieren
APA
Faizan, M. A., Khalid, I., Yeo, A., Fadel, M. M., Mcmahon, A., Gavigan, P., O'Neill, S., Isweisi, E., Semova, G., Roche, E. F., Branagan, A., Meehan, J., & Molloy, E. J. (2026). Necrotising enterocolitis biomarkers: a systematic review. Frontiers in Pediatrics, 13. https://doi.org/10.3389/fped.2025.1652566
Vancouver
Faizan MA, Khalid I, Yeo A, Fadel MM, Mcmahon A, Gavigan P, et al. Necrotising enterocolitis biomarkers: a systematic review. Frontiers in Pediatrics. 2026;13. doi:10.3389/fped.2025.1652566
BibTeX
@article{Faizan2026,
author = {Faizan, Muhammad Ashhad and Khalid, Iffat and Yeo, Asten and Fadel, Magdalina Mazheda and Mcmahon, Alannah and Gavigan, Philip and O'Neill, Saffron and Isweisi, Eman and Semova, Gregana and Roche, Edna F and Branagan, Aoife and Meehan, Judith and Molloy, Eleanor J},
title = {Necrotising enterocolitis biomarkers: a systematic review},
journal = {Frontiers in Pediatrics},
year = {2026},
volume = {13},
doi = {10.3389/fped.2025.1652566}
}
EUVIMED